Bio-Techne (TECH) Fundamentals 2026 — P/E 101.0x, Revenue Analysis | SniperIQ
Bio-Techne (TECH) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bio-Techne's market cap?
Bio-Techne (TECH) has a market capitalization of approximately
What is Bio-Techne's P/E ratio?
Bio-Techne's trailing twelve-month P/E ratio is 101.0x, with a price-to-book (P/B) of 5.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Bio-Techne?
Bio-Techne runs a net profit margin of 9.0%, a gross margin of 65.0%, and an operating margin of 12.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bio-Techne generate?
Bio-Techne reported revenue of
Does Bio-Techne pay a dividend?
Bio-Techne offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Bio-Techne financially healthy?
Bio-Techne carries a debt-to-equity ratio of 0.14x and a current ratio of 4.49x, with a market beta of 1.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bio-Techne a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bio-Techne (TECH) the key facts are: market cap
Track Bio-Techne's full fundamentals live
Get Bio-Techne's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.